<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-99235</identifier>
<setSpec>0211-6995</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">No disponible</dc:title>
<dc:description xml:lang="en">Arterial hypertension is one of the major risk factors for the development of cardiovascular diseases such as heart failure, ischemic heart disease, chronic kidney disease and cerebrovascular events. Adequate blood pressure control is vital for the management of patients with vascular disease. New therapeutic alternatives are appearing on the horizon to improve the degree of blood pressure control in these patients, such as direct renin inhibitors, beta-blockers with additional properties, carotid receptor-stimulating devices and vaccination against arterial hypertension. Direct renin inhibitors are a new family of antihypertensive drugs that have so far shown a good antihypertensive effect and an additive effect on reduction of proteinuria in patients with diabetic nephropathy. Recent meta-analyses suggest that betablockers used as first-line treatment for uncomplicated arterial hypertension could have a less beneficial effect on the development of cardiovascular disease than other antihypertensive drugs. However, the emergence of new subtypes of beta-blockers with other hemodynamic and metabolic properties could change this conception. Carotid receptor-stimulating devices and vaccination against arterial hypertension, although not totally new therapies, are being revitalized, with preliminary results that suggest that they could be used for the treatment of arterial hypertension in patients with a specific profile. Although scientifically stimulating, the long-term beneficial effects of these new therapeutic alternatives on target-organ protection still need to be confirmed (AU)</dc:description>
<dc:creator>Santamaría Olmo, R</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La hipertensión arterial es uno de los principales factores de riesgo para el desarrollo de enfermedades cardiovasculares, tales como insuficiencia cardíaca, cardiopatía isquémica, enfermedad  renal crónica y accidentes cerebro vasculares. Un adecuado control de la presión arterial es de vital importancia para el manejo de los enfermos con patología vascular. Para mejorar el grado de  control de  la presión arterial en estos pacientes, están apareciendo en el horizonte nuevas alternativas  terapéuticas,  tales  como  los  inhibidores directos de  la  renina, betabloqueantes con propiedades adicionales, dispositivos estimuladores de los receptores carotídeos y la vacunación frente a la hipertensión arterial. Los inhibidores directos de la renina son una nueva familia de fármacos  antihipertensivos  que,  hasta  el momento,  han mostrado tener un buen efecto antihipertensivo y un efecto aditivo sobre la reducción de la proteinuria en pacientes con nefropatía diabética. Recientes meta-análisis sugieren que  los betabloqueantes podrían  tener un menor  efecto beneficioso sobre el desarrollo de enfermedad cardiovascular empleados como primera línea del tratamiento de la hipertensión arterial no complicada comparados con otros fármacos antihipertensivos. Sin embargo,  la aparición de(..) (AU)</dc:description>
<dc:source>Nefrologia;28(supl.5): 131-137, ene.-dic. 2008. ilus, tab</dc:source>
<dc:identifier>ibc-99235</dc:identifier>
<dc:title xml:lang="es">Novedades terapéuticas en el manejo de la HTA</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d322^s22073</dc:subject>
<dc:subject>^d2389^s22021</dc:subject>
<dc:subject>^d7152^s22057</dc:subject>
<dc:subject>^d23123^s22000</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d7005^s22073</dc:subject>
<dc:subject>^d962^s22073</dc:subject>
<dc:subject>^d29553^s22006</dc:subject>
<dc:type>article</dc:type>
<dc:date>200812</dc:date>
</metadata>
</record>
</ibecs-document>
